ÀüÁ¾¸ñÅä·Ð
PRO-VAC¢â ASF: Komipharm¡¯s Breakthrough Defense Against African Swine Fever
On April 16, 2026, Komipharm International Co., Ltd. achieved a historic milestone: receiving the official Animal Pharmaceutical Manufacturing Product Approval for our revolutionary vaccine, PRO-VAC¢â ASF. African Swine Fever (ASF) has devastated farm businesses worldwide, but you can finally stop the spread. In this video, we explore the groundbreaking science and rigorous clinical trials behind the world's most advanced Live Attenuated ASF vaccine.
2026³â 4¿ù 16ÀÏ, ÄÚ¹ÌÆÊ ÀÎÅͳ»¼Å³Î(ÁÖ)Àº Çõ½ÅÀûÀÎ ¾ÆÇÁ¸®Ä«µÅÁö¿º´(ASF) ¹é½ÅÀÎ PRO-VAC¢â ASF¿¡ ´ëÇÑ µ¿¹°¿ë ÀǾàÇ° Á¦Á¶ ¹× ÆǸŠÇã°¡(AMPA)¸¦ °ø½ÄÀûÀ¸·Î ȹµæÇÏ¸ç ¿ª»çÀûÀÎ ÀÌÁ¤Ç¥¸¦ ¼¼¿ü½À´Ï´Ù.
¾ÆÇÁ¸®Ä«µÅÁö¿º´(ASF)Àº Àü ¼¼°è ³ó°¡¿¡ ¸·´ëÇÑ ÇÇÇظ¦ ÀÔÇûÁö¸¸, ÀÌÁ¦ ¿©·¯ºÐµµ ±× È®»êÀ» ¸·À» ¼ö ÀÖ½À´Ï´Ù.
ÀÌ ¿µ»ó¿¡¼´Â ¼¼°è¿¡¼ °¡Àå ¾Õ¼± »ý¹é½ÅÀÎ PRO-VAC¢â ASF ¹é½ÅÀÇ È¹±âÀûÀÎ °úÇÐ ±â¼ú°ú ¾ö°ÝÇÑ ÀÓ»ó ½ÃÇè °úÁ¤À» ¼Ò°³ÇÕ´Ï´Ù.
ÇØ¿ÜÁøÃâ ¸ñÇ¥·Î Á¦ÀÛ µÈ °ÍÀ¸·Î º¸¿©Áý´Ï´Ù
¿µ»ó³»¿ë Áß Áß¿äºÎºÐÀ» ¹ø¿ªÇغ¸¸é...
1. ASF ¹ÙÀÌ·¯½ºÀÇ À§Çù°ú º¯ÀÌÀÇ ÃâÇö
º¹ÀâÇÑ ±¸Á¶: ASF´Â 150°³ ÀÌ»óÀÇ À¯ÀüÀÚ·Î ±¸¼ºµÈ °Å´ë DNA ¹ÙÀÌ·¯½º·Î, ¸é¿ª ¹ÝÀÀÀ» ȸÇÇÇÏ´Â ´É·ÂÀÌ ¶Ù¾î³³´Ï´Ù. [00:14]
ÇÏÀ̺긮µå º¯ÀÌÀÇ Åº»ý: 2019³â Áß±¹À» ½ÃÀÛÀ¸·Î 1Çü(Genotype I)°ú 2Çü(Genotype II)ÀÌ ¼¯ÀÎ ÀçÁ¶ÇÕ ÇÏÀ̺긮µå º¯ÀÌ°¡ ÃâÇöÇß½À´Ï´Ù. [01:21]
ÀÌ º¯Á¾Àº 2019 Áß±¹ºÏºÎ.2023³â º£Æ®³², 2024³â ű¹À¸·Î ±Þ°ÝÈ÷ È®»êµÇ¸ç ±âÁ¸ ¹æ¿ª ü°è¸¦ À§ÇùÇÏ°í ÀÖ½À´Ï´Ù. [01:29]
2. ±âÁ¸ ¹é½ÅÀÇ Ä¡¸íÀû °áÇÔ: '¹ÙÀÌ·¯½º ¹èÃâ(Shedding)'
ºÒ¿ÏÀüÇÑ ¹æ¾î: Ãʱâ 1¼¼´ë »ý¹é½ÅµéÀº À¯ÀüÀÚ °á¼ÕÀÌ ºÒÃæºÐÇÏ¿© µÅÁö´Â »ì¸®Áö¸¸, µÅÁö ¸ö¿¡¼ ¾àÇØÁø ¹ÙÀÌ·¯½º¸¦ °è¼Ó ¹èÃâÇÏ°Ô ¸¸µì´Ï´Ù. [02:13]
º¯ÀÌÀÇ °¡¼ÓÈ: ¹èÃâµÈ ¹é½Å ¹ÙÀÌ·¯½º°¡ ¾ß»ý ¹ÙÀÌ·¯½º¿Í ¸¸³ª À¯ÀüÀÚ¸¦ ±³È¯ÇÏ¸é¼ ´õ °·ÂÇÏ°í ÅëÁ¦ ºÒ°¡´ÉÇÑ ÇÏÀ̺긮µå º¯Á¾À» ¸¸µé¾î³»´Â '»ý¹°ÇÐÀû °øÀå' ¿ªÇÒÀ» ÇÏ°Ô µË´Ï´Ù. [02:39]
3. ÄÚ¹ÌÆÊÀÇ ÇÙ½É ±â¼ú: 'Zero-Shedding' (¹«¹èÃâ)
ÀÌÁß À¯ÀüÀÚ °á¼Õ(Delta LVR): ÄÚ¹ÌÆÊÀº I177L°ú LVR À¯ÀüÀÚ¸¦ µ¿½Ã¿¡ Á¦°ÅÇÑ µ¶ÀÚÀûÀÎ ¸ðµ¨À» »ç¿ëÇÕ´Ï´Ù. [04:17]
¿ÏÀü ¸é¿ª(Sterile Immunity): ÀÌ ¹é½ÅÀº ü³»¿¡¼ »çÀÌÅäÄ«ÀÎ(IL-12P40) ºÐºñ¸¦ ÃËÁøÇØ T¼¼Æ÷ ¸é¿ªÀ» Á¶±â¿¡ È°¼ºÈÇÕ´Ï´Ù. [04:31]
°á°úÀûÀ¸·Î ¹ÙÀÌ·¯½º°¡ ü³»¿¡¼ º¹Á¦µÇ°Å³ª ¿ÜºÎ·Î ¹èÃâµÇ´Â °ÍÀ» ¿ÏÀüÈ÷ Â÷´ÜÇÏ¿© º¯ÀÌÀÇ °í¸®¸¦ ²÷¾î¹ö¸³´Ï´Ù. [04:48]
4. ÀÓ»ó µ¥ÀÌÅÍ ¹× ¾ÈÀü¼º °ËÁõ (Çʸ®ÇÉ ¸ðµ· ÀÓ»ó)
¹ø½Ä ¾ÈÀü¼º: ÀÓ½ÅÇÑ ¾ÏµÅÁö(¸ðµ·) ´ë»ó ÀÓ»ó¿¡¼ »ç»êÀ² 2.5%¸¦ ±â·ÏÇÏ¿© ´ëÁ¶±º(2.4%)°ú Â÷ÀÌ°¡ ¾øÀ½À» Áõ¸íÇß½À´Ï´Ù. [05:23]
ÀçÀӽŠ¼º°ø·ü: ¹é½Å Á¢Á¾±ºÀº 100%ÀÇ ÀçÀӽŠ¼º°ø·üÀ» º¸¿© ´ëÁ¶±º(85%)º¸´Ù ¿ì¼öÇÑ °á°ú¸¦ ³ªÅ¸³Â½À´Ï´Ù. [05:41]
ÀÌ´Â ¹é½ÅÀÌ µÅÁöÀÇ »ý½Ä ´É·Â¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ÁÖÁö ¾ÊÀ½À» ÀǹÌÇÕ´Ï´Ù.
5. ½ÃÀå °æÀï·Â ¹× ±Û·Î¹ú ÀÎÇÁ¶ó
¾ÐµµÀû ¹æ¾î ¹üÀ§: º£Æ®³² ÇÏÀ̺긮µå º¯ÀÌ°¡ ±ÞÁõ(2025³â 71.6% Á¡À¯)ÇÏ´Â »óȲ¿¡¼, ÄÚ¹ÌÆÊÀÇ 'Zero-Shedding' ¾ÆÅ°ÅØó°¡ Àü¼¼°è ÃÖÃÊÀÌÀÚ À¯ÀÏÇÑ ÃÖÁ¾´ë¾ÈÀ¸·Î Á¦½ÃµË´Ï´Ù. [06:09]
»ý»ê ¹× ƯÇã: 53³â ¿ª»çÀÇ ÄÚ¹ÌÆÊÀº 135°³ÀÇ Æ¯Ç㸦 º¸À¯ÇÏ°í ÀÖÀ¸¸ç, Àü ¼¼°è ´ë·® »ý»ê¿¡ ÇÊ¿äÇÑ BSL-2+ ÀÎÁõ ½Ã¼³À» °®Ãá , ¼¼°èÃÖÃÊ ¹ÙÀÌ·¯½º ºñ¹èÃâ ¹é½Å °ø±ÞóÀÔ´Ï´Ù. [06:46]
